A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
Journal of Hepatocellular Carcinoma · 2025-09 · Volume 12 · 2123-2137
DOI: 10.2147/jhc.s456712 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2025-09. Verfasst von Weihong Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Hepatology, The 5th Medical Center of the PLA General Hospital, Beijing, People's Republic of China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Senior Department of Hepatology, The 5th Medical Center of the PLA General Hospital, Beijing, People's Republic of China.
- Chinese PLA Medical School, Beijing, People's Republic of China.
- Guizhou Medical University, Guizhou, People's Republic of China.
Zitieren
APA
Ma, W., Li, Y., Lu, Y., Liang, Z., Yu, H., Han, J., Liu, J., Wang, W., Peng, C., & Cheng, J. (2025). A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, Volume 12, 2123-2137. https://doi.org/10.2147/jhc.s456712
Vancouver
Ma W, Li Y, Lu Y, Liang Z, Yu H, Han J, et al. A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2025;Volume 12:2123-2137. doi:10.2147/jhc.s456712
BibTeX
@article{Ma2025,
author = {Ma, Weihong and Li, Yinyin and Lu, Yinying and Liang, Zhipeng and Yu, Hongli and Han, Jie and Liu, Jiaqi and Wang, Wenjing and Peng, Caiyun and Cheng, Jiamin},
title = {A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma},
journal = {Journal of Hepatocellular Carcinoma},
year = {2025},
volume = {Volume 12},
pages = {2123--2137},
doi = {10.2147/jhc.s456712}
}
EUVIMED